Data from open-label extension of VOYAGE 1 study of guselkumab in adults with moderate to severe psoriasis released

At week 252, 84% of those in the combined group (initially randomised to guselkumab plus those who crossed over from placebo) achieved a PASI 90 response and 82.4% achieved an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear), with no new safety signals.

Biospace Inc.